

Paul B. Fisher and Magdalena Leszczyniecka
U.S. Serial No. : Not Yet Known
(Continuation Application of
PCT/US00/02920, filed 2 February 2000)
Filed: Herewith
Page 2

Please amend claims 6, 8, 13, 14 and 21 as follows:

- a²*
6. (Amended) A nucleic acid molecule comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of the nucleic acid molecule of claim 3.
- a³*
8. (Amended) An antisense nucleic acid molecule comprising a sequence complementary to the nucleic acid of claim 3.
- a⁴*
13. (Amended) A host vector system for the production of a protein having the biological activity of OLD-137, OLD-139, OLD-142, OLD-175 protein which comprises a vector which comprises the isolated nucleic acid molecule of claim 3 or 8 in a suitable host.
- a⁵*
14. (Amended) A method of producing a protein having the biological activity of OLD-35, OLD-64, OLD-137, OLD-139, OLD-142, OLD-175 protein which comprises growing the host vector system of claim 13 under conditions permitting production of the protein and recovering the protein so produced.
21. (Amended) A protein encoded by the isolated nucleic acid molecule of claim 3.

REMARKS

This application is a continuation of PCT International Application No. PCT/US00/02920, filed 2 February 2000, designating the United States of America, which is a continuation-in-part of U.S. Serial No. 09/243,277, filed February 2, 1999. Accordingly, the parent application, PCT International Application No. PCT/US00/02920, is pending today in the United States of America pursuant to 35 U.S.C. §363, and the subject continuation application is co-pending therewith in fulfillment of the provisions of 35 U.S.C. §120.

By this Preliminary Amendment, applicants have hereinabove amended the specification on page 1 to insert the continuation data. Applicants maintain that the amendments made hereinabove do not raise any issue of new matter. Accordingly, applicants respectfully request entry of the Amendment.